非小细胞肺癌T790M基因突变的研究进展

Advanced Research on T790M Mutation in Non-small Cell Lung Cancer

第三代EGFR-TKI奥西替尼可以显著延长第一代或第二代EGFR-TKI治疗失败后发生EGFR-T790M突变的晚期非小细胞肺癌患者的无进展生存期。因此,T790M的检测在后续的个体化治疗中就显得至关重要。而无论是组织活检还是液体活检,总有一部分病人无法进行再次检测,或者在再次检测中结果为阴性,那么该部分患者中是否仍有患者存在T790M突变,也可以从奥西替尼的治疗中获益呢?现已有一些研究对T790M突变的临床病理特征进行了探讨,有望为该类患者的治疗选择提供参考。而现有研究表明,T790M突变不仅为第三代EGFR-TKI的用药指征,还与EGFR-TKI的疗效及患者的生存期相关。本文将着重对T790M基因的临床病理特征及其与EGFR-TKI疗效及患者生存期的相关性的研究进展进行综述。

The third-generation EGFR-TKI axitinib significantly prolonged progression-free survival in patients with advanced non-small cell lung cancer who developed EGFR-T790 M mutations after first-or second-generation EGFR-TKI failure.Therefore,the detection of T790 M is crucial in subsequent individualized treatments.Whether it is a tissue biopsy or a liquid biopsy,there are always some patients who are unable to retest,or if the results are negative in the retest,then whether there are still patients in this part of the patients with T790 M mutation,can also be obtained from the treatment of oxytinib Benefit?Several studies have examined the clinicopathological features of the T790 M mutation and are expected to provide a reference for the treatment options of such patients.However,existing studies have shown that the T790 M mutation is not only a third-generation EGFR-TKI indication,but also related to the efficacy of EGFR-TKI and the survival of patients.This article will focus on the clinical and pathological features of the T790 M gene and its research progress in the relationship between EGFR-TKI efficacy and patient survival.